Drug intelligence / Profile preview

CTH522 + CAF09b

Development stage: Unknown
Lead developer: Statens Serum Institut
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

CTH522 + CAF09b is a vaccine candidate for Chlamydia trachomatis. CTH522 is a recombinant, engineered version of the Major Outer Membrane Protein (MOMP), comprising heterologous immunorepeats of VD4 regions from four genital C. trachomatis serovars (D, E, F, and G). The vaccine is adjuvanted with CAF09b, a liposomal adjuvant. In clinical trials, CTH522 + CAF09b has demonstrated the ability to induce neutralizing IgG and IgA in serum and in the female reproductive tract, as well as cell-mediated immune responses. The vaccine showed stronger immunogenicity compared to CTH522 adjuvanted with aluminum hydroxide.

Targets

OmpA (Outer membrane protein A)

Beyond the preview

Go deeper on CTH522 + CAF09b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTH522 + CAF09b.

Explore the full profile